KH815 / Chengdu Kanghong Pharma - LARVOL DELTA

Translational study and First-in-Human (FIH) study design of KH815, a novel dual-payload TROP-2 targeted Antibody-Drug Conjugate (ADC), in patients with advanced solid tumors (ESMO 2025) - No abstract available

Clinical • Metastases • P1 data • Oncology • Solid Tumor

KH815, a novel dual-payload TROP2-directed antibody-drug conjugate, shows potent antitumor efficacy in pre-clinical tumor model (AACR 2025) - "Several antibody-drug conjugates (ADCs) targeting TROP2, such as sacituzumab govitecan and datopotamab deruxtecan, have shown promising anti-tumor activity in multiple solid tumors, particularly in breast cancer. The non-GLP toxicity study in cynomolgus monkeys provided evidence of the favorable safety profile of KH815, the highest non-severely toxic dose (HNSTD) is 40 mg/kg/dose.In summary, KH815, an ADC with dual toxins and unique mechanisms of action, displayed superior anti-tumor effects, the ability to overcome drug resistance, and an acceptable safety profile in preclinical studies. These findings support the potential of KH815 as a promising advanced therapeutic candidate for tumors."

Preclinical • Breast Cancer • Oncology • Solid Tumor

KH815, a novel dual-payload TROP2-directed antibody-drug conjugate, shows potent antitumor efficacy in pre-clinical tumor model [WITHDRAWN] (AACR 2025) - "Several antibody-drug conjugates (ADCs) targeting TROP2, such as sacituzumab govitecan and datopotamab deruxtecan, have shown promising anti-tumor activity in multiple solid tumors, particularly in breast cancer. The non-GLP toxicity study in cynomolgus monkeys provided evidence of the favorable safety profile of KH815, the highest non-severely toxic dose (HNSTD) is 40 mg/kg/dose.In summary, KH815, an ADC with dual toxins and unique mechanisms of action, displayed superior anti-tumor effects, the ability to overcome drug resistance, and an acceptable safety profile in preclinical studies. These findings support the potential of KH815 as a promising advanced therapeutic candidate for tumors."

Preclinical • Breast Cancer • Oncology • Solid Tumor

First-In-Human Study in Participants with Advanced Solid Tumors (clinicaltrials.gov) - P1 | N=30 | Not yet recruiting | Sponsor: Chengdu Kanghong Biotech Co., Ltd.

New P1 trial • Oncology • Solid Tumor